United Therapeutics Corporation (UTHR) Fair Value 2026

UTHR · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.6 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (8/100)

Quick Summary — As of 2026-08-27, United Therapeutics Corporation (UTHR) trades at $527.91, versus a $551.45 median fair value across its 11 active models — 4.5% above the current price. QOC: 9.6/10. Value Trap Risk: 8/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $712.79.

Key Facts

Ticker
UTHR
Price
$527.91
Quality Score
9.6/10
Value Trap Risk
8/100
Models Active
11/13
Last Updated
Strength: Bayesian DCF suggests +35.0% upside with 74% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is United Therapeutics Corporation (UTHR) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, United Therapeutics Corporation (UTHR) appears fairly valued as of : the median of 11 independent fair value estimates is $551.45, within 4.5% of the current price of $527.91. Estimates range from $331.01 to $1105.28. UTHR scores 9.6/10 on fundamental quality and 8/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. UTHR’s +4.5% gap is narrower than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy United Therapeutics Corporation Stock in 2026? →

What Fair Value Does Each Model Give UTHR?

11 Intrinsic Value Models vs. Current Price ($527.91)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $712.79 +35.0%
Intrinsic · High Conviction
 $420.76 -20.3%
Ensemble · Medium Conviction
 $551.45 +4.5%
Scenario · High Conviction
 $554.57 +5.0%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is UTHR's Fair Value Range?

Spread across 11 independent models · $331.01 to $1105.28

CirclFi's 11 active models place United Therapeutics Corporation (UTHR) between $331.01 and $1105.28 per share, a spread of 140% of the median. The median of that range — $551.45 — is the fair value CirclFi publishes for UTHR, against a current price of $527.91.

Low · EROICHigh · Markov DDM
$331.01median $551.45$1105.28
Where the range comes from
Most bearish modelEROIC Spread$331.01
Most bullish modelMarkov DDM$1105.28
Model agreement5 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for UTHR. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on UTHR, not a CirclFi price target. How each model works →

What Is United Therapeutics Corporation (UTHR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, United Therapeutics Corporation presents a highly debated valuation profile at its current price of $527.91. The median intrinsic value is estimated at $551.45 (+4.5% median upside), masking a wide model spread between the 5 bullish models and 5 bearish models. Model dispersion is worth noting: Markov DDM targets $1,105.28 (+109.4%), versus EROIC at $331.01 (-37.3%). This +146.7% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About UTHR?

11 of 13 models are currently active for UTHR. Of these, 6 models suggest upside while 5 models suggest overvaluation. Taken together, their median fair value for UTHR is $551.45 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $712.79 on its own, implying +35.0% upside from the current price. See which stocks rank higher →

How Does UTHR Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, UTHR ranks #1 by Quality of Company score. CirclFi's QOC score of 9.6/10 evaluates 32 fundamental signals. A score of 9.6 places UTHR in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, United Therapeutics Corporation competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is UTHR a Value Trap?

CirclFi's Value Trap algorithm assigns UTHR a score of 8/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for United Therapeutics Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, United Therapeutics Corporation is rated at 9.6/10. This elite-tier score ranks among the highest-quality businesses in our coverage universe.

The gap between the most bullish and bearish model spans +146.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every UTHR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across UTHR's 11 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy United Therapeutics Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

9 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

AKANAkanda Corp.QOC 1.3AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4SXTCChina SXT Pharmaceuticals, Inc.QOC 1.4ZTSZoetis Inc.QOC 9.3UPCUniverse Pharmaceuticals INCQOC 1.8LNTHLantheus Holdings, Inc.QOC 9.3ETONEton Pharmaceuticals, Inc.QOC 7.2OGIOrganigram Global Inc.QOC 6.1BTAIBioXcel Therapeutics, Inc.QOC 4.7

Read investment analysis: AKAN · AMPH · SXTC · ZTS · UPC · LNTH · ETON · OGI · BTAI

Which Other Stocks Have a Similar Quality Score to UTHR?

7 companies across all industries closest to UTHR’s Quality of Company score of 9.6/10.

MANHManhattan Associates, Inc.QOC 9.6GOOGAlphabet Inc.QOC 9.6FFIVF5, Inc.QOC 9.6FIXComfort Systems USA, Inc.QOC 9.6BKTIBK Technologies CorporationQOC 9.6MSFTMicrosoft CorporationQOC 9.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MANH · GOOG · FFIV · FIX · BKTI · MSFT · NVDA

Where Does UTHR Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

UTHR is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About United Therapeutics Corporation’s Valuation?

What is United Therapeutics Corporation's intrinsic value in 2026?

CirclFi puts United Therapeutics Corporation (UTHR)'s intrinsic value at $551.45 — the median of 11 independent model estimates as of 2026-08-27, ranging from $331.01 to $1105.28. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $712.79 on its own. The Quality of Company score is 9.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is UTHR overvalued or undervalued right now?

At $527.91, 6 of 11 active models suggest UTHR may be undervalued, while 5 indicate potential overvaluation. The median of all 11 fair value estimates is $551.45, within 4.5% of the current price of $527.91 — a consensus view that UTHR is fairly valued. The assessment depends on which methodology best fits United Therapeutics Corporation's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 9.6 mean for UTHR?

United Therapeutics Corporation's QOC of 9.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on UTHR?

CirclFi analyzes UTHR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on UTHR?

Of the 11 models currently active on UTHR, Markov DDM is the most bullish at $1105.28 per share, and EROIC Spread is the most bearish at $331.01. CirclFi's published fair value for UTHR is the median of that range, $551.45, not either extreme. The gap between the two ends equals 140% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is UTHR a value trap in 2026?

United Therapeutics Corporation's Value Trap score is 8/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, United Therapeutics Corporation (UTHR) has a median fair value of $551.45 — within 4.5% of the current price of $527.91 — as of 2026-08-27.” Source: circlfi.com/stock/UTHR/ · Methodology
Primary sources for this UTHR valuation
  • Financial statements: United Therapeutics Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001082554) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for UTHR as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on UTHR.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for UTHR Unlock All 11 — $39/mo